|本期目录/Table of Contents|

[1]温鹏,韩玉娟,杨剑,等.肝细胞癌患者缩短普美显强化MRI检查中肝胆期时间的探索[J].天津医科大学学报,2022,28(04):433-435,441.
 WEN Peng,HAN Yu-juan,YANG Jian,et al.Exploration of shortening the duration of hepatobiliary phase in EOB enhanced MRI for patients with hepatocellular carcinoma[J].Journal of Tianjin Medical University,2022,28(04):433-435,441.
点击复制

肝细胞癌患者缩短普美显强化MRI检查中肝胆期时间的探索(PDF)
分享到:

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
28卷
期数:
2022年04期
页码:
433-435,441
栏目:
技术与方法
出版日期:
2022-07-20

文章信息/Info

Title:
Exploration of shortening the duration of hepatobiliary phase in EOB enhanced MRI for patients with hepatocellular carcinoma
文章编号:
1006-8147(2022)04-0433-04
作者:
温鹏12韩玉娟2杨剑2纪盛章1
(1.天津医科大学第四中心临床学院影像科,天津300142;2.天津市第三中心医院放射科,天津300170)
Author(s):
WEN Peng12HAN Yu-juan1YANG Jian1JI Sheng-zhang2
(1.Radiology Center,Fourth Clinical,Tianjin Medical University,Tianjin 300142,China;2.Department of Radiology,Tianjin Third Central Hospital,Tianjin 300170,China)
关键词:
普美显肝细胞肝癌MRI肝胆期时间
Keywords:
Gd-EOB-GTPAhepatocellular carcinomaMRIduration of hepatobiliary phase
分类号:
R735.7
DOI:
-
文献标志码:
A
摘要:
目的:探究肝细胞癌(HCC)患者应用15 min肝胆期普美显的临床诊断效果。方法:选择本院收治的80例HCC患者,同一患者分别进行15 min和20 min普美显肝胆期延迟扫描(分为15 min组和20 min组)。比较两组视觉模拟评分(VAS)、患者配合度评分、病灶检出率评分以及图像指标评分。结果:15 min组VAS明显低于20 min组(t=3.14,P=0.003),并且配合度得分更高(t=2.36,P=0.02);两组均表现出有效的病灶检出率(P=0.18);3个动态时期(动脉期、门静脉期和延迟期)均反映出良好的HCC血供情况(均P>0.05);两组对象图像指标评分(Cm和CER)结果对于HCC不同分化程度(高分化、中分化以及低分化)均未表现出显著性差异(均P>0.05)。结论:使用15 min普美显肝胆期时间检测与目前临床使用的20 min在影像结果上无显著差异,但是HCC患者的配合度更高,体验更佳。
Abstract:
Objective:To investigate the clinical diagnostic effects of 15 min Gd-EOB-GTPA(EOB) in patients with hepatocellular carcinoma(HCC). Methods:A total of 80 patients with HCC were randomly divided into two groups:15 min and 20 min EOB delayed hepatobiliary phase scan group(15 min group and 20 min group respectively).Visual analogue scale(VAS),patient compliance score,lesion detection rate score and image index score were observed independently. Results:The VAS values of the 15 min group was significantly lower than theVAS values of the 20 min group(t=3.14,P=0.003),and the score of compliance was higher(t=2.36,P=0.02),both groups showed an effective lesion detection rate(P=0.18),three dynamic phases(arterial phase,portal phase and delayed phase) showed good blood supply of HCC(all P > 0.05).There was no significant difference between the two groups in the degree of differentiation of HCC(high differentiation,moderate differentiation and low differentiation,all P > 0.05). Conclusion:There is no significant difference between 15 min PME and 20 min EOB in imaging diagnosis of HCC,but the patients with HCC have better cooperation and experience,which is worthy of clinical application in future.

参考文献/References:

[1] 刘芷希,汪业胜,王伟炳. 中国1990-2017年乙型肝炎疫情的变化趋势研究[J]. 中华流行病学杂志,2021,42(4):613-619.
[2] 崔富强,王富珍,郑徽,等. 大力推动我国实现消除病毒性肝炎公共卫生威胁的目标[J]. 中华流行病学杂志,2021,42(9):1523-1526.
[3] KULIK L,EL-SERAG H B.Epidemiology and management of hepatocellular carcinoma[J]. Gastroenterology,2019,156(2):477-491.
[4] 樊璐璐,谢双双,张坤,等. 慢性肝病肝功能正常或Child-Pugh A级患者增强CT与普美显增强MRI诊断HCC流出征象观察期相选择[J]. 中国临床医学影像杂志,2018,29(11):775-781.
[5] 罗鸿,张福洲,王文轩,等. 普美显增强MRI对原发性肝癌诊断和鉴别诊断的临床价值分析[J]. 影像研究与医学应用,2020,4(9):13-15.
[6] 陈莉玲,梁雪梅,贺小红,等. 普美显2种注射方法对MRI增强扫描的图像质量影响及护理分析[J]. 现代医药卫生,2019,35(24):3838-3841.
[7] 许晓亮,李新瑜,鲁果果. CT与MRI增强扫描肝癌患者应用普美显的临床价值分析[J]. 医学影像学杂志,2020,30(3):515-518.
[8] 何琨. 普美显磁共振增强成像用于鉴别肝硬化结节与结节型肝癌价值探析[J]. 影像研究与医学应用,2019,3(8):52-53.
[9] 《中华肝脏病杂志》编辑委员会, 中华医学会肝病学分会肝癌学组. 肝细胞癌癌前病变的诊断和治疗多学科专家共识(2020版)[J]. 临床肝胆病杂志,2020,36(3):514-519.
[10] 张艳,刘影. 普美显动态增强 MRI和动态增强 CT 对肝细胞肝癌血供的评估与病理对照分析[J]. 临床放射学杂志,2021,40(7):1334-1339.
[11] GOODWIN M D,DOBSON J E,SIRLIN C B,et al. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents[J]. Radiographics,2011,31(6):1547-1568.
[12] CHOL J W,LEE J M,KIM S J,et al. Hepatocellular carcinoma:imaging patterns on gadoxetic acid -enhanced MR Images and their value as an imaging biomarker[J]. Radiology,2013,267(3):776-786.
[13] RAMAN S S,LEARY C,BLUEMKE D A,et al. Improved characterization of focal liver lesions with liver-specific gadoxetic acid disodium-enhanced magnetic resonance imaging: a multicenter phase 3 clinical trial[J]. J Comput Assist Tomogr,2010,34(2):163-172.
[14] TANIMOTO A,LEE J M, MURAKAMI T, et al. Consensus report of the 2nd international forum for liver MRI[J]. Eur Radiol,2009,19(1):S975-S989.
[15] 韩玉娟,于长路,贾科峰,等. 不同注射流率及动脉期期相选择对肝脏普美显增强MRI图像质量的影响[J]. 临床放射学杂志,2016, 35(1):138-142.
[16] 王家友,赵勇,伍小勇,等. 普美显磁共振对早期肝硬化合并小肝癌的诊断价值[J]. 中国CT和MRI杂志,2019,17(8):92-95.
[17] 曾凌宇. 普美显磁共振增强成像鉴别诊断小肝癌与肝硬化结节的应用价值[J]. 现代医用影像学,2020,29(8):1503-1505.
[18] 蒋逆立,汤伟,何浩强,等. 优化屏气方案对普美显增强动脉期图像的价值[J]. 影像研究与医学应用,2021,5(11):12-14.
[19] KANATA N,YOSHIKAWA T,OHNO Y,et al. HCC-to-liver contrast on arterial-dominant phase images of EOB-enhanced MRI comparison with dynamic CT[J]. Magn resonimaging,2013,31(1):17-22.

相似文献/References:

[1]袁华尊,孙保存,赵秀兰,等.Amotl2促进肝细胞肝癌血管生成拟态及EMT形成[J].天津医科大学学报,2016,22(04):277.
 YUAN Hua-zun,SUN Bao-cun,ZHAO Xiu-lan,et al.Amotl2 promotes vasculogenic mimicry and epithelial-mesenchymal transition in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2016,22(04):277.
[2]郑 鹏,李 强.BCLC-B期肝细胞肝癌治疗效果分析[J].天津医科大学学报,2016,22(05):421.
 ZHENG Peng,LI Qiang.Analysis of therapeutic effect on patients with BCLC -B hepatocellular carcinoma[J].Journal of Tianjin Medical University,2016,22(04):421.
[3]张宁,赵秀兰,李勇莉,等.Nrf2促进肝癌细胞的迁移与侵袭能力[J].天津医科大学学报,2020,26(05):408.
 ZHANG Ning,ZHAO Xiu-lan,LI Yong-li,et al.Nrf2 promotes the migration and invasion in hepatocellular carcinoma[J].Journal of Tianjin Medical University,2020,26(04):408.

备注/Memo

备注/Memo:
基金项目 天津市卫计委重点攻关项目(14KG113)
作者简介:温鹏(1986-),男,主管技师,硕士在读,研究方向:影像医学与核医学;通信作者:纪盛章,E-mail:jsz0549@163.com。
更新日期/Last Update: 2022-07-20